Sign In
Buy NKTR
$59.23
+0.670 (+1.14%)
At Close: Jun 03, 2026
5 Small Drug Stocks to Buy as Industry Recovery Picks Up
09:46am, Wednesday, 07'th Jan 2026
Innovation is at its peak in the Zacks Medical-Drugs industry. SLNO, NKTR, RIGL, IRWD and MRKR may prove to be good additions to one's portfolio.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR
11:50am, Tuesday, 06'th Jan 2026
NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Nektar Therapeutics (“Nektar” or the “Company”) (NASDAQ: NKTR). Such investors
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR
10:00am, Thursday, 01'st Jan 2026
NEW YORK, Jan. 1, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Nektar Therapeutics ("Nektar" or the "Company") (NASDAQ: NKTR). Such investors are advised to
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR
12:40pm, Tuesday, 30'th Dec 2025
NEW YORK, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Nektar Therapeutics (“Nektar” or the “Company”) (NASDAQ: NKTR). Such investors
The Zacks Analyst Blog Mineralys, Lyell, Insmed and Nektar
03:35am, Friday, 26'th Dec 2025
Mineralys Therapeutics leads a biotech surge, with four drug stocks up over 50% in 2025 and catalysts lining up for more upside in 2026.
4 Drug, Biotech Stocks Rising More Than 50% in 2025 With Room to Grow
11:56am, Wednesday, 24'th Dec 2025
MLYS, LYEL, NKTR and INSM rise more than 50% in 2025 as clinical wins, FDA approvals and M&A deals revive sector momentum heading into 2026.
Nektar Therapeutics (NKTR) Stock Slides Despite Analyst Optimism On Alopecia Data
04:19pm, Monday, 22'nd Dec 2025
Nektar Therapeutics stock is trading lower Monday afternoon as the market continues to assess mixed topline results from the Phase 2b REZOLVE-AA trial of rezpegaldesleukin.
Nektar Therapeutics: Alopecia Update And A Look At The Road Ahead For Rezpeg
04:49pm, Wednesday, 17'th Dec 2025
Nektar Therapeutics's results from REZOLVE-AA, a trial of rezpegaldesleukin in alopecia areata, have failed to stimulate a rally in the stock. Even with concerns about statistical significance in the
Nektar Therapeutics (NKTR) Discusses Topline Results From REZOLVE-AA Phase 2b Study of rezpegaldesleukin in Alopecia Areata Transcript
Nektar Alopecia Trial Misses Endpoint, Hits Significance After Patient Exclusion
11:30am, Tuesday, 16'th Dec 2025
Nektar Therapeutics (NASDAQ: NKTR) on Tuesday revealed topline results from the 36-week induction treatment period of the Phase 2b REZOLVE-AA trial of investigational rezpegaldesleukin.
SAN FRANCISCO , Dec. 15, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on development of novel immunology therapies, today announced it will h
Here's Why Nektar Therapeutics (NKTR) is a Great Momentum Stock to Buy
01:01pm, Monday, 08'th Dec 2025
Does Nektar Therapeutics (NKTR) have what it takes to be a top stock pick for momentum investors? Let's find out.
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06:00pm, Friday, 05'th Dec 2025
SAN FRANCISCO , Dec. 5, 2025 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today announced that the Organization and Compensation Committee of Nektar's Board of Directors granted non-qualified st
Contrasting Nektar Therapeutics (NASDAQ:NKTR) & Pivotal Therapeutics (OTCMKTS:PVTTF)
01:40am, Thursday, 04'th Dec 2025
Pivotal Therapeutics (OTCMKTS:PVTTF - Get Free Report) and Nektar Therapeutics (NASDAQ: NKTR - Get Free Report) are both medical companies, but which is the superior investment? We will contrast the t
Wall Street Analysts Believe Nektar (NKTR) Could Rally 64.53%: Here's is How to Trade
10:56am, Monday, 01'st Dec 2025
The average of price targets set by Wall Street analysts indicates a potential upside of 64.5% in Nektar (NKTR). While the effectiveness of this highly sought-after metric is questionable, the positiv
